Cancer Biopsy Market Size, Share and Trends 2026 to 2035

What is the Cancer Biopsy Market Size?

The global cancer biopsy market size is accounted at USD 36.55 billion in 2025 and predicted to increase from USD 43.42 billion in 2026 to approximately USD 196.68 billion by 2035, representing a CAGR of 18.33% from 2026 to 2035.

Cancer Biopsy Market Key Takeaways

• North America led the global market with the highest market share of 47% in 2025.
• By type, the tissue biopsy segment is estimated to capture the biggest revenue share in 2025.
• By type, the liquid biopsy segment is anticipated to grow at a remarkable CAGR between 2026 and 2035.
• By product, the kits and consumables segment is predicted to register the maximum market share of 61% in 2025.
• By application, the breast cancer segment is estimated to hold the highest market share in 2025.

Cancer Biopsy Market Growth Factors

The removal of tissue for the purpose of examining it for disease is known as a biopsy. Any region of the body can be used to collect tissue samples. Biopsies can be done in a variety of methods. Some biopsies entail taking a little bit of tissue with a needle, while others entail surgically removing a suspected lump or nodule. The imaging tests like MRIs and CT scans can assist detect lumps or abnormal tissue, but they cannot distinguish the difference between cancerous and non-cancerous cells. The only approach to diagnose most malignancies is to take a biopsy and collect cells for further analysis.

The growing elderly population, together with the rising prevalence of cancer indications, is likely to drive the cancer biopsy market expansion. Furthermore, the introduction of liquid biopsy procedures is projected to boost the cancer biopsy market forward. In the field of oncology diagnostics, many procedures such as skin, needle, bone marrow, endoscopic, and surgical biopsies are used on a large scale. The needles biopsies are regarded a favored tool for early detection of patients among these techniques. However, benefits of fine needle aspiration needle biopsies, such as reduced invasion and faster results, have the cancer biopsy market expansion.

The liquid biopsy for cancer diagnosis, prognosis, screening, and treatment has increased competition and capabilities in the cancer biopsy market significantly. The key market players are taking significant steps to enter the cancer biopsy market and are conducting liquid biopsies, which are projected to drive the cancer biopsy market's growth in clinical settings. The liquid biopsy is being utilized to diagnose advanced cancer in individuals who are unable to undergo a tissue biopsy.

The liquid biopsy can also be used to determine targeted therapy or clinical trial eligibility for patients for whom tissue-based testing is not appropriate or available. The liquid biopsy provides oncologists with real-time information about a tumor and is a quick, minimally invasive, and cost-effective diagnostic. These tests have the potential to reveal residual tumor cells, early recurrence diagnosis, and treatment efficacy.

While the issues connected with cancer biopsy pose significant obstacles for technology vendors, laboratories, and clinicians, patients who want to avoid the genuine hazards, potential pain, and high costs associated with tissue biopsy have a strong demand for liquid biopsy. Furthermore, the ability to track treatments and detect disorder early, as well as collect data across the tumor, gives patients a better chance of receiving appropriately targeted therapy.

In terms of instruments, kits, and consumables, cancer biopsy has seen a number of technological advancements. The development of effective products associated with biopsies is critical as liquid biopsy becomes a multimodal tool of diagnosis in the field of clinical oncology. Despite the fact that existing instruments are widely utilized, they have a number of flaws. The introduction of new technologies, on the other hand, is predicted to dramatically enhance the need for instruments in the coming years. Several new companies are concentrating on developing equipment that can improve endoscopy -based biopsies.

Cancer Biopsy Market Outlook

[[market_outlook]]

Market Scope

Cancer Biopsy Market Segment Insights

[[segment_insights]]

Cancer Biopsy Market Regional Insights

[[regional_insights]]

Cancer Biopsy Market Value Chain Analysis

[[value_chain]]

Cancer Biopsy Market Companies

• Myriad Genetics Inc.
• Guardant Health Inc.
• Exact Sciences Corporation
• Bio-Rad Laboratories Inc.
• Agena Bioscience Inc.
• Personal Genome Diagnostics Inc.
• Exosome Diagnostics Inc.
• ANGLE Plc.
• F. Hoffmann-La Roche Ltd.

Cancer Biopsy Market Segments Covered in the Report

[[segment_covered]]